ADMA BIOLOGICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ADMA BIOLOGICS, INC. (ADMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 2.59% for the 3-month period ending 2018-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2019-05-08
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-03-31 was 2.59%, a 13.10% increase year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-03-31 was 2.29%.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 2.18%, a 44.37% increase from fiscal 2016.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2016 was 1.51%.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2014 was 2.19%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2018-03-31 | 2.59% 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | 2.18% 10-K · filed 2018-03-29 | |||
| 2017-03-31 | 2.29% 10-Q · filed 2018-05-14 | |||
| 2016-12-31 | 1.51% 10-K · filed 2018-03-29 | |||
| 2014-12-31 | 2.19% 10-K · filed 2016-03-23 | |||
| 2014-09-30 | 2.20% 10-Q · filed 2015-11-10 | |||
| 2013-06-30 | 1.24% 10-Q · filed 2013-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |